Okairos

Basel, Switzerland Founded: 2007 • Age: 19 yrs Acquired By GSK
Developer of vaccines against a range of infectious diseases

About Okairos

Okairos is a Healthcare company based in Basel (Switzerland) founded in 2007, and was acquired by GSK in May 2013. Developer of vaccines against a range of infectious diseases. Okairos has raised $20.53 million across 2 funding rounds from investors including GSK, Life Sciences Partners and Versant Ventures. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.

Company details

Okairos was founded in 2007 in Basel, Switzerland, within the biotechnology sector focused on infectious diseases. Vaccines are developed targeting malaria and hepatitis C as primary programs, while HIV, Ebola, and respiratory syncytial virus (RSV) initiatives remain in developmental stages. Operations center on advancing these vaccine candidates through research and clinical pathways.

  • Headquarters Basel, Switzerland
  • Stage Acquired
  • Sectors
    Healthcare
  • Website okairos.com
  • Social LinkedIn
  • Acquired by GSK (May 2013)
Key Metrics
  • Total Equity Funding
    $20.53M (USD)

    in 2 rounds

  • Latest Funding Round
    $20.53M (USD), Series B

    Sep 2010

  • Investors
    GSK

    & 6 more

  • Acquired by
    GSK

    (May 2013)

Funding Insights of Okairos

Okairos has successfully raised a total of $20.53M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $20.53 million completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $20.53M
  • Total Rounds 2
  • Last Round Series B β€” $20.53M
  • Investors Count 6

All 2 funding rounds of Okairos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2010$20.53MSeries B–Versant Ventures
Jun 2007Seed––
Valuation history

7 investors in total: 7 institutional.

Investors in Okairos

Okairos has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include GSK, Life Sciences Partners and Versant Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
versantventures.com
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
boehringer-ingelheim-venture.com
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
biomedvc.comBasel, Switzerland
Investments are made in innovative life science companies globally.
nvfund.comBasel, Switzerland
Private equity investments in life sciences businesses are managed.
1998lspvc.comAmsterdam, Netherlands
EQT is recognized as a global investment organization focused on value creation.
eqtgroup.com
Developer of pharmaceuticals and vaccines for various therapeutic areas
1715gsk.comBrentford, United Kingdom
Premium access

Investor details for Okairos

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Okairos

4 dated milestones of Okairos across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Okairos is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series B, of $20.5M.
  4. Exit Acquired by GSK.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Okairos

Premium access

Complete news archive for Okairos

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Okairos

Okairos was founded in 2007.

Okairos is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.

Okairos is a funded company, having raised a total of $20.53M across 2 funding rounds to date.

Okairos was founded in 2007 in Basel, Switzerland, within the biotechnology sector focused on infectious diseases. Vaccines are developed targeting malaria and hepatitis C as primary programs, while HIV, Ebola, and respiratory syncytial virus (RSV) initiatives remain in developmental stages. Operations center on advancing these vaccine candidates through research and clinical pathways.

Okairos has 7 investors. Key investors include GSK, Life Sciences Partners, Versant Ventures, Boehringer Ingelheim Venture Fund, and BioMedPartners.

Yes. Okairos was acquired by GSK in May 2013.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available